A game-changer in the fight against obesity has landed on UK pharmacy shelves: Wegovy, a once-daily pill containing semaglutide. While this oral medication offers an alternative for those struggling to lose weight, it's essential to note that it won't be available through the NHS – meaning patients will need to fund their treatment privately.
The introduction of Wegovy in tablet form provides another option for individuals who prefer not to use injections. Research has shown that both forms of semaglutide are equally effective when combined with a balanced diet and regular exercise, but taking the pill requires adherence to a strict daily routine: it must be taken on an empty stomach at least 8 hours after eating, at least 30 minutes before any other food, drink or medication – and only with a small amount of plain water.
Eligibility for Wegovy is similar to that for the injection. To access the treatment, individuals must have a Body Mass Index (BMI) of 30 or above (classified as obese), or a BMI between 27 and 30 (overweight) combined with specific weight-related health conditions like Type 2 diabetes or high blood pressure. A consultation – either online or in person – is mandatory to ensure the treatment is suitable for the individual's medical profile.
Common side effects associated with semaglutide, whether in pill or injection form, mainly involve gastrointestinal issues such as nausea, vomiting, constipation and diarrhoea. Less common but more serious complications can occur, including low blood sugar, pancreatitis or severe allergic reactions. Patients are strongly advised to thoroughly review the patient information leaflet and discuss any pre-existing medical conditions or current medications with their doctor before starting treatment.
The typical starting dose for Wegovy is 1.5mg daily for one month, gradually increasing after consultation to a maximum recommended dose of 25mg daily. As with the injection, it can take several months to achieve full therapeutic benefits – and there's a risk of weight regain if the medication is discontinued. For those currently using the 2.4mg semaglutide injection privately, switching to Wegovy tablets under medical supervision is possible, but dosing and treatment plans will vary depending on individual circumstances.